These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 15368730

  • 1. Which patients with atrial fibrillation do not need anticoagulation therapy with warfarin?
    Guthmann RA.
    Am Fam Physician; 2004 Sep 01; 70(5):917-8. PubMed ID: 15368730
    [No Abstract] [Full Text] [Related]

  • 2. Evidence-based emergency medicine. Anticoagulation or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.
    Diner BM.
    Ann Emerg Med; 2003 Jan 01; 41(1):141-3. PubMed ID: 12514695
    [No Abstract] [Full Text] [Related]

  • 3. Choosing between warfarin (Coumadin) and aspirin therapy for patients with atrial fibrillation.
    Ebell MH.
    Am Fam Physician; 2005 Jun 15; 71(12):2348-50. PubMed ID: 15999873
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Preventing stroke in patients with atrial fibrillation.
    Edds W, Newton W.
    J Fam Pract; 2000 Jan 15; 49(1):8-9. PubMed ID: 10678330
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Patterns of anticoagulation in patients hospitalized with atrial fibrillation: warfarin is underused in paroxysmal atrial fibrillation.
    Marcu CB, Ghantous AE, Caracciolo EA, Donohue TJ.
    Conn Med; 2003 Jan 15; 67(10):595-8. PubMed ID: 14677339
    [Abstract] [Full Text] [Related]

  • 9. A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention.
    Thomson R, Eccles M, Wood R, Chinn DJ.
    Med Decis Making; 2007 Jan 15; 27(4):438-47. PubMed ID: 17641140
    [Abstract] [Full Text] [Related]

  • 10. A comparison of rural and urban anticoagulation management of atrial fibrillation in a southwest Missouri health system.
    Hover AR, Rogers JT, Hunt C.
    Mo Med; 2003 Jan 15; 100(1):94-7. PubMed ID: 12664713
    [Abstract] [Full Text] [Related]

  • 11. Re: CJ Green, DC Hadorn, K Bassett, A Kazanjian. Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. 1997;13:811-5.
    Laupacis A.
    Can J Cardiol; 1998 May 15; 14(5):659, 662; author reply 663, 665. PubMed ID: 9627518
    [No Abstract] [Full Text] [Related]

  • 12. Stroke prevention in atrial fibrillation: are we following the guidelines?
    Pusser BE, Robertson SL, Robinson MD, Barton C, Dobson LA.
    N C Med J; 2005 May 15; 66(1):9-13. PubMed ID: 15786672
    [Abstract] [Full Text] [Related]

  • 13. Re: CJ Green, DC Hadorn, K Bassett, A Kazanjian, Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. 1997;13:811-5.
    Mant MJ.
    Can J Cardiol; 1998 May 15; 14(5):663; author reply 663, 665. PubMed ID: 9627519
    [No Abstract] [Full Text] [Related]

  • 14. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators.
    Am Heart J; 2006 Nov 15; 152(5):967-73. PubMed ID: 17070169
    [Abstract] [Full Text] [Related]

  • 15. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H, Selçuk MT, Maden O.
    Anadolu Kardiyol Derg; 2007 Mar 15; 7(1):54-8. PubMed ID: 17347079
    [Abstract] [Full Text] [Related]

  • 16. Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
    Hammwöhner M, Goette A.
    J Cardiovasc Pharmacol; 2008 Jul 15; 52(1):18-27. PubMed ID: 18594479
    [Abstract] [Full Text] [Related]

  • 17. The need for new oral anticoagulants in clinical practice.
    Hylek EM.
    J Cardiovasc Med (Hagerstown); 2009 Aug 15; 10(8):605-9. PubMed ID: 19571764
    [Abstract] [Full Text] [Related]

  • 18. Anticoagulation control in atrial fibrillation: optimizing risks and benefits.
    Alsheikh-Ali AA, Estes NA.
    Circ Cardiovasc Qual Outcomes; 2008 Nov 15; 1(2):72-3. PubMed ID: 20031792
    [No Abstract] [Full Text] [Related]

  • 19. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
    Mant JW.
    Thromb Haemost; 2008 Jul 15; 100(1):14-5. PubMed ID: 18612531
    [No Abstract] [Full Text] [Related]

  • 20. Re: 'Avoidance hierarchies and preferences for anticoagulation--semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarin'.
    Choudhury A, Chowdhury SR, Connolly DL.
    Age Ageing; 2005 Jul 15; 34(4):416; author reply 416-7. PubMed ID: 15955774
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.